Close Menu

Qiagen

The German biotech firm said its lateral flow blood test does not detect subclinical HPV infection but picks up on HPV-induced cancers and pre-cancers.

The test will identify patients with squamous cell head and neck cancer caused by specific HPV infections for treatment with BioNTech's investigational BNT113.

The new consortium is aiming to make comprehensive genomic profiling accessible to advanced cancer patients in the US, to help inform their treatment decisions.

Qiagen received CE IVD marking for its NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Test and for a saliva collection kit for its single-plex NeuMoDx SARS-CoV-2 assay.

Qiagen will develop T cell-based lab tests to detect prior exposure to SARS-CoV-2 using discoveries from TScan's target discovery platform.

The Australian diagnostics firm is working with Qiagen on lab-based antigen and serology tests and plans to launch its own US point-of-care and home tests.

Qiagen said that growth in the quarter was primarily driven by COVID-19 testing products and improving customer demand for other products.

The company's Q3 sales reflect ongoing demand for COVID-19 testing products and improved customer demand in other areas of the firm's portfolio.

Qiagen has benefited from unexpected tailwinds due to COVID-19 testing and envisions post-pandemic growth with recently acquired NeuMoDx as a key contributor.

Pages